title: Premenstrual dysphoric disorder: a review for the treating practitioner.
abstract: Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS), is characterized by physical and behavioral symptoms that cause marked social impairment during the last half of the menstrual cycle. Symptoms are believed to result from the interaction of central neurotransmitters and normal menstrual hormonal changes. Treatment usually begins with lifestyle changes, over-the-counter medications, and if needed, selective serotonin reuptake inhibitors. Physicians should be aware of the risks of many of the alternative therapies commonly touted in the popular press.
authors.affiliation: Department of General Internal Medicine, Women's Health Center at The Gault Women's Health and Breast Pavilion, The Cleveland Clinic Foundation, OH 44195, USA. kaurg@ccf.org
authors.forename: Gurjit
authors.initials: G
authors.lastname: Kaur
authors.forename: Lilian
authors.initials: L
authors.lastname: Gonsalves
authors.forename: Holly L
authors.initials: HL
authors.lastname: Thacker
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019587:Dietary Supplements; D005260:Female; D006176:Gynecology / Q000379:methods; D006801:Humans; D010052:Ovariectomy / Q000379:methods; D008517:Phytotherapy / Q000379:methods; D011293:Premenstrual Syndrome / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D011379:Prognosis; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000928:Antidepressive Agents; D017367:Selective Serotonin Reuptake Inhibitors